Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definitive treatment.

Ended Awarded

Contract number
HT009022FG4A00029
Awardee
Awarding agency
Obligated
$17,480

Award facts

Contract value 100% obligated
$17,480.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Sterling, VA, USA

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

Sofie Co., a subsidiary of Sofie Biosciences, Inc., has been awarded a firm fixed price contract valued at seventeen thousand four hundred eighty dollars by the Defense Health Agency. The contract calls for Sofie to provide a radiopharmaceutical needed for treatment of a prostate cancer patient with metastatic lesions, in support of the Agency's healthcare programs. Performance will occur in Sterling, Virginia through September 30th, 2022. No set-aside designation was applied to this procurement.

Quick answers

Who was awarded contract HT009022FG4A00029?

HT009022FG4A00029 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on April 14, 2022.

How much is contract HT009022FG4A00029 worth?

The government has obligated $17,480 on HT009022FG4A00029.

Is contract HT009022FG4A00029 an order under another contract?

Yes. HT009022FG4A00029 is a BPA call under HT001421A0014, a blanket purchase agreement.

Was contract HT009022FG4A00029 competed?

The extent of competition for HT009022FG4A00029 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login